Theravance Biopharma TBPH Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's total current liabilities?
- Theravance Biopharma (TBPH) reported total current liabilities of $31.78M in Q1 2026.
- How has Theravance Biopharma's total current liabilities changed year-over-year?
- Theravance Biopharma's total current liabilities increased by 0.9% year-over-year, from $31.5M to $31.78M.
- What is the long-term trend for Theravance Biopharma's total current liabilities?
- Over 5 years (2020 to 2025), Theravance Biopharma's total current liabilities has grown at a -20.9% compound annual growth rate (CAGR), from $123.57M to $38.3M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.